Into the matrix: targeting fibroblasts in pulmonary fibrosis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: This review describes the challenges created by the existence of multiple molecular pathways leading to fibrosis and proposes that attention be focused on targeting the fibroblasts and myofibroblasts which themselves produce multiple cytokines and growth factors as well as the extracellular matrix, which is the hallmark of fibrotic lung disease. RECENT FINDINGS: The last 20 years have seen remarkable progress in our understanding of the molecular pathogenesis of pulmonary fibrosis leading to multiple programmes in drug discovery, and there are currently 15 actively recruiting trials registered on http://www.clinicaltrials.gov. Unfortunately, at this time only one new drug, pirfenidone, has progressed to approval for use in patients. Part of the frustration is that drugs that are effective in targeting inflammatory pathways have been ineffective in lung fibrosis. This may result from the inability to treat patients early in the disease process but it is also likely that pathways independent of inflammation can drive fibrosis. SUMMARY: We further propose that this approach should inhibit fibrosis independent of cell type or the signalling cascade that is activating these cells. We are hopeful that the next 20 years will see many more therapeutic options for patients suffering with fibrotic lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“Death usually occurs within 3–5 years following diagnosis [2,3].”
BackgroundEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964 · cited 1×
“N-acetylcysteine (NAC), a mucolytic drug with antioxidant properties, was shown to reduce the forced vital capacity (FVC) decline rate when used in combination triple therapy with prednisone and azathioprine [44].”
BackgroundTager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823 · cited 5×
“466 signalling by IL13 and IL17 results in the production of inflammatory mediators such as IL6 and IL8 and thrombin-mediated signalling results in the production of CCL2 [30,43].”
BackgroundInfluentialMi, S., Li, Z., Yang, H.-Z., Liu, H., Wang, J.-P., Ma, Y.-G., Wang, X.-X., Liu, H.-Z., Sun, W., & Hu, Z.-W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004081 · Cited by 370 · cited 1×
“In-vivo studies using the bleomycin-induced fibrosis model have demonstrated a role for IL17A in the development of fibrosis [32].”
BackgroundTGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
Murray, L. A., Chen, Q., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Peng, X., Gulati, M., Homer, R. J., Russell, T., van Rooijen, N., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.013 · Cited by 362 · cited 1×
“during chronic inflammation may also be a source of active TGFb and platelet-derived growth factor (PDGF), which can exert profibrotic and proliferative effects on fibroblasts [19,20].”
BackgroundBarron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008959 · Cited by 203 · cited 1×
“[33] recently reported that peripheral T-lymphocytes from IPF patients had diminished CD28 expression, expressed aberrant markers of activation and produced large amounts of proinflammatory cytokines compared with autologous CD4þ T cells, changes that were associated with poor prognosis.”
BackgroundPlatelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis
Lo Re, S., Lecocq, M., Uwambayinema, F., Yakoub, Y., Delos, M., Demoulin, J.-B., Lucas, S., Sparwasser, T., Renauld, J.-C., Lison, D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0516oc · Cited by 128 · cited 1×
“Unau 1070-5287 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Furthermore, cells of the T-reg subtype produce PDGF-B that activates fibroblasts and contributes to pulmonary fibrosis [34].”
Background
Cited by
The myofibroblast matrix: implications for tissue repair and fibrosis
Klingberg, F., Hinz, B., & White, E. S. (2013) · The Journal of Pathology · doi:10.1002/path.4104 · Cited by 776
Hinz, B. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.07.009 · Cited by 424
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368
The role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
Lodyga, M., Cambridge, E., Karvonen, H. M., Pakshir, P., Wu, B., Boo, S., Kiebalo, M., Kaarteenaho, R., Glogauer, M., Kapoor, M., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aao3469 · Cited by 181
Metadata
- Authors
- Sivakumar, P., Ntolios, P., Jenkins, G., & Laurent, G.
- Venue
- Current Opinion in Pulmonary Medicine
- Published
- 2012-09
- Volume
- 18
- Issue
- 5
- Pages
- 462-469
- ISSN
- 1070-5287 (ISSN-L)
- OpenAlex
- W2024260450
- Cited by
- 67
- References
- 11
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Into the matrix: targeting fibroblasts in pulmonary fibrosis. https://app.cochat.ai/papers/10.1097/mcp.0b013e328356800f
- The paper
- Sivakumar, P., Ntolios, P., Jenkins, G., & Laurent, G. (2012). Into the matrix: targeting fibroblasts in pulmonary fibrosis. Current Opinion in Pulmonary Medicine. https://doi.org/10.1097/mcp.0b013e328356800f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.